Condition

Type 1 Diabetes Mellitus

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 718 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials718

Recruiting59

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

VV-14299 and VV-14300 for the Treatment of Type 1 DiabetesNCT07829302 · 2026-10-01

VV-14300 for the Treatment of Type 1 DiabetesNCT07831798 · 2026-10-01

Exploring Skin Barrier Function, Recurrence of Diabetes Device-Related Contact Dermatitis, and Evaluation of Hydrocolloid and Silicone-Based Patches for Its Prevention in Children and Adolescents With Type 1 DiabetesNCT07767461 · 2026-09-04

Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 DiabetesNCT07804849 · 2026-08-20

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATGNCT07216391 · 2026-07-29

Acute Metabolic Effects of Tirzepatide in Type 1 DiabetesNCT06820281 · 2026-07-07

Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 DiabetesNCT07149142 · 2026-07-01

Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1DNCT07593625 · 2026-05-25

Simultaneous Measurement and Responsive Treatment - Part 2NCT07655076 · 2026-05-19

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood SugarNCT07284511 · 2026-05-19

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes MellitusNCT07142252 · 2026-05-14

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 SystemNCT07579702 · 2026-05-13

Pediatric Insulin Plan Calculator for T1DM ManagementNCT07427134 · 2026-05-03

Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 DiabetesNCT07585994 · 2026-05-01

The Postprandial Hypo-Avoid StudyNCT07427251 · 2026-04-27

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 DiabetesNCT07548996 · 2026-04-27

Polycystic Ovary Syndrome in Type 1 DiabetesNCT07490964 · 2026-04-01

Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With SulfasalazineNCT07416656 · 2026-03-10

Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DMNCT07296276 · 2026-02-09

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321 · 2026-02-04

AI-Assisted Remote Insulin Pump Optimization in T1DMNCT07732777 · 2026-01-28

Gamification Intervertion in Children With Type 1 DiabetesNCT07409701 · 2026-01-25

Examining Multilevel Factors Affecting Participation in Physical Activity Among Adolescents With Type 1 Diabetes Using the Socio-Ecological ModelNCT07568028 · 2026-01-02

Twiist Postmarket Surveillance Study for Type 1 DiabetesNCT07356089 · 2025-12-09

Characterization of Type 1 Diabetes Subgroup: An Artificial Intelligence Analysis of Clinical and Glucometric FeaturesNCT07461805 · 2025-11-04

The MICRON Study - A Steno 1 SubstudyNCT07270172 · 2025-10-27

Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in AdultsNCT07434154 · 2025-10-01

A Study of GNTI-122 in Adults Recently Diagnosed With T1DNCT06919354 · 2025-09-03

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068 · 2025-08-06

Study on the Improvement of Metabolic Indicators in Type 1 Diabetes PatientsNCT07144696 · 2025-08-05

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesNCT06791291 · 2025-07-25

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 DiabetesNCT06609356 · 2025-07-03

Feasibility of a Tailored Online Self-compassion InterventionNCT07051005 · 2025-06-18

Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 DiabetesNCT07483879 · 2025-06-13

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes MellitusNCT06575426 · 2025-06-10

Fake Carbs Practice With AID System - MiniMed 780G in Children and Adolescents With T1D.NCT07179471 · 2025-06-04

Real-world Study on the Effectiveness and Safety of Control-IQ Technology in Teenagers With Type 1 Diabetes Engaging in Regular Physical ActivityNCT06876207 · 2025-06-01

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)NCT06783309 · 2025-05-12

Effect of Inulin Supplementation on Glycaemic Control and Immunological Parameters in Type 1 Diabetes (2024)NCT07050888 · 2025-05-09

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.NCT06810726 · 2025-04-15

Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusNCT06704672 · 2025-04-14

Basic Hematological Parameters and Coagulation Profile in Type 1 Diabetic ChildrenNCT06897904 · 2025-04-01

Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin DoseNCT06686329 · 2025-03-17

The Skin Barrier in Users of Diabetes DevicesNCT06856954 · 2025-03-10

Carb Counting vs. Simplified Qualitative Meal-Size EstimationNCT06687434 · 2024-12-15

An Adaptive Design Study of MTX228NCT06474598 · 2024-11-14

Establishment of Screening Pathway for High-Risk Population of Type 1 DiabetesNCT07468474 · 2024-09-01

A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in TeenagersNCT06709755 · 2024-07-10

Immunotherapy with Autologous Tregs in T1DMNCT06708780 · 2023-04-12

Registry of Patients Living With Type 1 DiabetesNCT03720197 · 2019-02-20

The Effects of Fluoxetine and/or DHEANCT03228732 · 2017-12-19

Chinese Alliance for Type 1 Diabetes Multi-center Collaborative ResearchNCT04096794 · 2016-09-01

Type 1 Diabetes Extension StudyNCT02734277 · 2016-06-08

Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic PatientsNCT03463564 · 2016-01-01

Fr1da Early Diagnosis and Care of Type 1 DiabetesNCT04039945 · 2015-02-01

Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes.NCT02306005 · 2014-11-01

Long Term Follow up of Recipients of Functional Islet AllograftsNCT01999374 · 2013-03-01

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft LossNCT01999361 · 2009-01-01

Long Term Surveillance of Islet Transplant Recipients Following Complete Graft LossNCT02000687 · 2008-12-01

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.NCT07614412 · 2027-01-01

NOT_YET_RECRUITING

Common interventions

Leading sponsors

Sanofi28 University of Virginia27 Eli Lilly and Company14 Medtronic MiniMed, Inc.14 Sansum Diabetes Research Institute12 University of Colorado, Denver12 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)11 National Institute of Allergy and Infectious Diseases (NIAID)10 Adocia9 AstraZeneca9 Mannkind Corporation8 Nemours Children's Clinic8 Stanford University8 Institut de Recherches Cliniques de Montreal7 University of Ljubljana, Faculty of Medicine7

Trial status mix

COMPLETED481

RECRUITING59

UNKNOWN52

TERMINATED44

NOT_YET_RECRUITING29

ACTIVE_NOT_RECRUITING28

WITHDRAWN18

ENROLLING_BY_INVITATION3

NO_LONGER_AVAILABLE3

APPROVED_FOR_MARKETING1

Phase mix

NA281

PHASE2128

PHASE1110

PHASE366

PHASE446

EARLY_PHASE111

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.